Skip to content

Are there differences in central nervous system processing in patients with refractory chronic cough?

Are there differences in central nervous system processing in patients with refractory chronic cough?

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN88737146
Enrollment
70
Registered
2018-12-10
Start date
2020-02-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic cough Respiratory

Interventions

Volunteers will be asked to attend a screening visit to determine eligibility for the study. Here their medical history and demographics will be recorded
their blood pressure and heart rate will be measured
and their height and weight will be measured. The volunteer will be asked to complete some questionnaires and perform a spirometry test. If the results of all of these tests show that the subject is s

Sponsors

Wythenshawe Hospital Research and Development Directorate
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Males and females 18-80 years, inclusive 2. Non-smokers >6 months; ex-smokers <20 pack years Healthy Volunteers 3. No clinically relevant abnormalities based on the medical history, physical examination, vital signs 4. No history of current or significant past respiratory disease, specifically a diagnosis of asthma 5. Spirometry within normal limits Chronic Cough Patients 6. Have a refractory chronic cough as defined by BTS guidelines 7. No evidence of asthma

Exclusion criteria

Exclusion criteria: 1. Routine contraindications to fMRI scanning e.g. certain metal implants, recent surgery, extreme claustrophobia etc 2. Any condition that may increase airway/circulating levels of ATP/adenosine e.g. chronic cardiac failure, chronic hypoxia, vigorous exercise within 48 hours 3. Pregnant or breastfeeding 4. Upper or lower respiratory tract infection or significant change in pulmonary status within 4 weeks of enrolment 5. Any therapy that may modulate cough (e.g. ACE inhibitors, opioids, gabapentin). Patients can be included if they are willing/able to discontinue these for the study duration and a suitable washout period

Design outcomes

Primary

MeasureTime frame
Brain connectivity assessed using an fMRI scan at the final visit

Secondary

MeasureTime frame
All outcomes are only measured once (baseline): 1. Cough frequency, recorded by an ambulatory cough monitor 2. Cough reflex sensitivity, as determined by a cough challenge 3. The impact of cough on daily life and activities, measured using the Cough Quality of Life Questionnaire (CQLQ) 4. Depression, measured using The Centre for Epidemiological Studies depression scale (CED-S) 5. Interoception, measured using The Multidimensional Assessment of Interceptive Awareness (MAIA)

Countries

England, United Kingdom

Contacts

Public ContactRachel Dockry
cough.research@manchester.ac.uk+44 (0)161 291 5031

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026